Evidence map›Paper›PMID 41086389›Full record

ArticleJournal of medicinal chemistry2025

Structure-Activity Relationship of Antischistosomal Aryl Hydantoin (AR102).

Derek A Leas, Cécile Häberli, Karen L White, David M Shackleford, Jeremy O Jones, Michael Campbell, Jianbo Wu, Deepender Kaushik, Yuxiang Dong, Alexander I Wallick and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Derek A LeasCollege of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198-6125, United States.
Cécile HäberliDepartment of Medical Parasitology and Infection Biology, Swiss Tropical Institute, Socinstrasse 57, Basel CH-4002, Switzerland.
Karen L WhiteCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
David M ShacklefordCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Jeremy O JonesDepartment of Cancer Biology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California 91010, United States.
Michael CampbellCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Jianbo WuCollege of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198-6125, United States.
Deepender KaushikCollege of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198-6125, United States.
Yuxiang DongCollege of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198-6125, United States.ORCID 0000-0003-1412-3178
Alexander I WallickDepartment of Biology, University of Nebraska at Omaha, Omaha, Nebraska 68182, United States.
Susan A CharmanCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.ORCID 0000-0003-1753-8213
Jennifer KeiserDepartment of Medical Parasitology and Infection Biology, Swiss Tropical Institute, Socinstrasse 57, Basel CH-4002, Switzerland.
Paul H DavisDepartment of Biology, University of Nebraska at Omaha, Omaha, Nebraska 68182, United States.ORCID 0000-0002-0526-3841
Jonathan L VennerstromCollege of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, Nebraska 68198-6125, United States.ORCID 0000-0003-0075-2336

Funding

Optimization of Antischistosomal ChemotypesR01AI116723 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VENNERSTROM, JONATHAN L · 2015 to 2024
$6.2M
NIAID NIH HHS R01 AI116723
6 · The paper itself

Abstract

As exemplified by Ro 13-3978 (

Indexed as

HydantoinsSchistosomicidesAnimalsHumansMaleMiceStructure-Activity RelationshipHydantoinsRo 13-3978Schistosomicides

Identifiers

PMID41086389
PMCPMC12910559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.